ARSEUS |
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| 04-11 | Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024 | |
| 04-11 | Fagron Reports Revenue Results for the First Quarter Ended 31 March 2024 | CI |
| Sales 2024 * | 841M 912M 1.24B | Sales 2025 * | 895M 970M 1.32B | Capitalization | 1.32B 1.43B 1.96B |
|---|---|---|---|---|---|
| Net income 2024 * | 80M 86.7M 118M | Net income 2025 * | 95M 103M 140M | EV / Sales 2024 * | 1.85 x |
| Net Debt 2024 * | 233M 252M 344M | Net Debt 2025 * | 185M 201M 274M | EV / Sales 2025 * | 1.69 x |
| P/E ratio 2024 * |
16.4
x | P/E ratio 2025 * |
14.2
x | Employees | - |
| Yield 2024 * |
1.59% | Yield 2025 * |
1.73% | Free-Float | 94.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on ARSEUS
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 17-11-26 | |
Karin de Jong
DFI | Director of Finance/CFO | 45 | 08-04-30 |
Vera Bakker
COO | Chief Operating Officer | 52 | 22-05-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Koen Hoffman
CHM | Chairman | 56 | 16-07-31 |
| Director/Board Member | 64 | 18-12-31 | |
| Chief Executive Officer | 46 | 17-11-26 |
Fagron N.V. specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to pharmacists and hospitals, etc.
Sector
Pharmaceuticals
Calendar
2024-08-01
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +56.89% | 823B | |
| +39.52% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +13.74% | 239B | |
| +13.83% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B |
